Scholarlink

<p>The human microbiome has an enormous and multifaceted ecosystem of microorganisms like fungi, protozoa, bacteria, and viruses that live in our bodies, mainly in the gut, and is crucial in maintaining our health. The published evidence supports that they influence gut and brain health. Over the past decade, research has brought to light the possibility that diseases commonly found in the Western world, like type II diabetes, obesity, and inflammatory bowel disease (IBD), might be treatable through microbiome-modulating therapeutic interventions. This review discusses the emerging microbiome-targeted interventions and their therapeutic potential and mechanisms of action. Microbiota-based therapeutics for IBD can help to mitigate inflammation and restore the balance of microbes, utilizing a variety of inputs such as probiotics and fecal microbiota transplants (FMT). For example, the modification of gut microbiome has been accompanied by positive effects on insulin sensitivity and glycemic control in diabetes, and in other studies with type 2 diabetes, dietary interventions or prebiotic supplementation appeared to provide beneficial outcomes as well. The treatment of obesity has also significantly increased with methods of microbiome manipulation intertwined with the regulation of energy homeostasis and fat storage. Here, we review the progress of the advancement of different approaches to modulate gut microbiome, including probiotics, prebiotics, and FMT, and more specifically, we consider how these therapies affect gut microbial flora balance and function. Therefore, in addition to alleviating symptoms, these treatments may help change the underlying processes of illness. Future research endeavors include enhancing the effectiveness of these medicines by comprehensively studying individual microbiome differences and using tailored techniques. The current exploration of the gut microbiome has substantial potential for pioneering therapies, establishing a foundation for forthcoming advancements in managing chronic illnesses via manipulating the microbiome.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Microbiome modulating remedies for chronic diseases: a review of current interventions and future directions

  • 期刊论文

  • 发表日期：

    2026年4月20日

查看全文
  • Mahendra Pratap Swain,
  • Chetan Hasmukh Mehta,
  • Bhrath Singh Padya,
  • Shreya Sharma,
  • Varalakshmi Velagacherla,
  • Adwitiya Mitra,
  • Satyajit Mohanty,
  • Tuhin Mukherjee

摘要

The human microbiome has an enormous and multifaceted ecosystem of microorganisms like fungi, protozoa, bacteria, and viruses that live in our bodies, mainly in the gut, and is crucial in maintaining our health. The published evidence supports that they influence gut and brain health. Over the past decade, research has brought to light the possibility that diseases commonly found in the Western world, like type II diabetes, obesity, and inflammatory bowel disease (IBD), might be treatable through microbiome-modulating therapeutic interventions. This review discusses the emerging microbiome-targeted interventions and their therapeutic potential and mechanisms of action. Microbiota-based therapeutics for IBD can help to mitigate inflammation and restore the balance of microbes, utilizing a variety of inputs such as probiotics and fecal microbiota transplants (FMT). For example, the modification of gut microbiome has been accompanied by positive effects on insulin sensitivity and glycemic control in diabetes, and in other studies with type 2 diabetes, dietary interventions or prebiotic supplementation appeared to provide beneficial outcomes as well. The treatment of obesity has also significantly increased with methods of microbiome manipulation intertwined with the regulation of energy homeostasis and fat storage. Here, we review the progress of the advancement of different approaches to modulate gut microbiome, including probiotics, prebiotics, and FMT, and more specifically, we consider how these therapies affect gut microbial flora balance and function. Therefore, in addition to alleviating symptoms, these treatments may help change the underlying processes of illness. Future research endeavors include enhancing the effectiveness of these medicines by comprehensively studying individual microbiome differences and using tailored techniques. The current exploration of the gut microbiome has substantial potential for pioneering therapies, establishing a foundation for forthcoming advancements in managing chronic illnesses via manipulating the microbiome.